PC
EIGR

Polar Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Polar Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-77
Closed -$680K – 300
2014
Q4 		$680K Buy
+77
New +$447K 0.01% 254

Other funds holding EIGR

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polar Capital's EIGR Position: Q1 2015 in Review

Polar Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2015, closing a stake of 77 shares — an estimated $680K sold.

Polar Capital first reported a position in EIGR in Q4 2014 and held it in 1 quarter. The position peaked at $680K in Q4 2014. 84 funds tracked by Wall St. Rank hold EIGR as of Q1 2015.

  • Polar Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Polar Capital sold 77 Eiger BioPharmaceuticals, Inc. shares in Q1 2015, an estimated $680K.
  • Polar Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Polar Capital's Eiger BioPharmaceuticals, Inc. position peaked at $680K in Q4 2014.
  • 84 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2015.

Based on Polar Capital's 13F filing for Q1 2015, filed 15 May 2015.